| abstract |
A transdermal pharmaceutical composition comprising a phosphodiesterase type-5 inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically excipient, wherein the transdermal pharmaceutical composition comprises an enhancer selected from the group of cocamidopropyl betaine, sodium lauroamphoacetate, quaternium-60, isostearamidopropyl morpholine lactate, dipropylene glycol and a combination thereof. |